Literature DB >> 22573714

The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences.

Alexander Sainz-Perez1, Annick Lim, Brigitte Lemercier, Claude Leclerc.   

Abstract

The accumulation of CD4(+) T regulatory cells (Treg) in tumor tissue is a widely described phenomenon in mouse models and in human cancer patients. Understanding the mechanisms by which Treg migrate and accumulate in tumors is important because they strongly influence the potential efficacy of many immunotherapies. In this study, we used immunoscope technology to analyze the T-cell receptor (TCR) repertoire of tumor-infiltrating T cells in non-TCR transgenic mice. Both tumor-infiltrating Tregs and T effector cells (Teff) displayed sequence profiles in the CDR3 region that were characteristic of biased repertoires seen during clonal cell expansions, implying that strong T-cell responses have occurred within the tumor tissue. By comparing the TCR sequences of tumor-infiltrating Tregs, we obtained evidence of the presence of so-called public TCR sequences that are common to many individuals yet were tumor-specific in nature. Such comparisons also suggested that the Treg-Teff conversion process is not an active process at the tumor site or tumor-draining lymph nodes. Our findings strongly suggest that Treg infiltration of tumor tissue is followed by marked proliferation of a few dominant T-cell clones in the tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573714     DOI: 10.1158/0008-5472.CAN-12-0277

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention.

Authors:  Joanna Domagala-Kulawik
Journal:  Transl Lung Cancer Res       Date:  2015-04

2.  CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Authors:  Hyun-Bae Jie; Patrick J Schuler; Steve C Lee; Raghvendra M Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa L Whiteside; Robert L Ferris
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

Review 3.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

4.  CD4+CD25+ regulatory T-cells: a potential target for treating patients with chronic HBV infection.

Authors:  Jiezuan Yang; Lanjuan Li
Journal:  Cell Mol Immunol       Date:  2017-08-07       Impact factor: 11.530

Review 5.  Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Authors:  Abigail E Overacre-Delgoffe; Dario A A Vignali
Journal:  Cancer Immunol Res       Date:  2018-08       Impact factor: 11.151

Review 6.  Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Authors:  Ee Lyn Lim; Klaus Okkenhaug
Journal:  Immunology       Date:  2019-07       Impact factor: 7.397

Review 7.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

8.  Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Authors:  Edith A Perez; Karla V Ballman; Kathy S Tenner; E Aubrey Thompson; Sunil S Badve; Helen Bailey; Frederick L Baehner
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

Review 9.  Informatics for cancer immunotherapy.

Authors:  J Hammerbacher; A Snyder
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

Review 10.  Tumor-infiltrating regulatory T cells: origins and features.

Authors:  Guoping Deng
Journal:  Am J Clin Exp Immunol       Date:  2018-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.